AYOXXA Biosystems Extends Series B

Andreas Richter new CFO of AYOXXA

Cologne, December 2nd, 2014                 
AYOXXA Biosystems GmbH, an international biotechnology company, announces the closing of a third round of Series B financing, bringing the total amount raised to 11.3 Mio. EUR in 2014. An additional 2.3 Mio. EUR were now invested by BioMedPartners AG, Basel and Grazia Equity GmbH, based in Stuttgart, Germany. Both leading European venture capital firms joined the group of established AYOXXA investors, who successfully closed second round in June 2014.            

“These funds will allow us to continue our production ramp-up efforts as well as to speed-up our global commercial activities”, said Dr. Andreas Schmidt CEO and Co-founder of AYOXXA Biosystems GmbH.

“We are excited to work with AYOXXA to drive the commercialization of this state-of-the-art multiplex-protein analysis technology”, Dr. Karsten Fischer, BioMedPartners AG commented. “Together with the unique small volume format, this method is enabling research, development and even potential diagnostic questions, so far inaccessible.”

Alec Rauschenbusch, Managing Partner of Grazia Equity GmbH: “With its highly innovative multiplexing system, AYOXXA is setting new standards for applications and analysis of high-value biological samples in the area of medical research and pharmacological screening”           

Additionally, the company announces that Andreas Richter will take over the function as CFO in AYOXXA’s Executive Management Team, effective January 1st 2015. “I am pleased to become part of AYOXXA’s business journey. The Series B financing round closed remarkably successful. We will leverage the financial assets to transform from a research-focused into a market-driven company. It is our goal to be partner of choice for life science researchers looking for a robust and flexible protein testing solution”, Richter stated.  
Andreas Richter is looking back on about 20 years' experience in the banking industry and as CFO for life science companies (including Direvo Biotech and 4-Antibody). He has a track record of several successful financing rounds and M&A transactions for growth companies. He already supported AYOXXA during the Series B round as financial advisor.    

Download Release_EN as PDF

Download Pressemitteilung_German as PDF     

Media Contact:        
Dr. Marion Lammertz
Marketing Manager Communications
AYOXXA Biosystems GmbH
BioCampus Cologne
Nattermannallee 1
50829 Cologne, Germany
marion.lammertz@ayoxxa.com
Phone: +49 (0) 221 222529 41

About AYOXXA

AYOXXA Biosystems GmbH, an international biotech company based in Cologne (Germany) and Singapore, has developed a proprietary technology platform for multiplex protein analysis. AYOXXA investors include BioMedPartners AG, b-to-v Partners AG, Creathor Venture, Grazia Equity GmbH, High-Tech Gründerfonds, HR Ventures, KfW Bankengruppe, NRW.BANK, Wellington Partners Venture Capital, private investors from US and Europe including Prof. Dr. Detlev Riesner, Co-founder of Qiagen and AYOXXA employees. Core to AYOXXA’s cutting-edge protein multiplexing system is a bead-based technology (IEBA) that yields 10,000-fold more data points than a standard 384-well ELISA. Together with lowest sample volume in the multiplex protein arena, an increased assay robustness, and readout with existing equipment, AYOXXA will innovate biomedical research, pharmacological screening and preclinical diagnostics development.

BioMedPartners AG
www.biomedvc.com

b-to-v Partners AG
www.b-to-v.com

Creathor Venture
www.creathor.de

Grazia Equity GmbH
www.grazia.com

High-Tech-Gründerfonds
www.en.high-tech-gruenderfonds.de

HR Ventures
www.hr-ventures.com

KfW Bankengruppe
www.kfw.de/kfw.de-2.html

NRW.BANK
www.nrwbank.com/en/index.html

Wellington Partners Venture Capital
www.wellington-partners.com/wp/index.html